FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988723429> ?p ?o ?g. }

• W1988723429 endingPage "569" @default.
• W1988723429 startingPage "558" @default.
• W1988723429 abstract "ObjectiveMultidrug resistance (MDR) in human B-cell lymphoma constitutes a major obstacle to the effectiveness of chemotherapy. The aim of this study was to investigate the molecular mechanism of MDR in B-cell lymphoma.Materials and MethodsThe B-cell lymphoma MDR sublines were developed by exposing the parental Daudi cells to stepwise increasing concentrations of doxorubicin. Interaction of Y-box binding protein-1 (YB-1) with the Y-box motif of the mdr1 gene promoters was studied by electrophoretic mobility shift assay. The effects of YB-1 on mdr1 promoter activity were examined by luciferase assay. After silencing of YB-1 gene by shRNA, the role of YB-1 nuclear translocation in the formation of induced MDR was examined. Expression of mdr1 and YB-1 was examined further after Daudi cells were pretreated with mitogen-activated protein kinase (MAPK) inhibitor PD98059 for 1 hour.ResultsDoxorubicin-resistant sublines was generated from the Daudi cell line by stepwise selection in doxorubicin. We found that acquisition of MDR is associated with enhanced YB-1 nuclear translocation and MAPK/extracellular signal-regulated kinase (ERK) activity. Electrophoretic mobility shift assay revealed that doxorubicin increased binding of YB-1 to the Y-box of mdr1 promoter. Luciferase reporter assays demonstrated that the Y-box region is essential for YB-1 regulation of mdr1 expression. The introduction of exogenous YB-1 shRNA into Daudi cells resulted in decreased levels of the expression of mdr1 gene and P-glycoprotein induced by doxorubicin. When Daudi cells were pretreated with MAPK inhibitor PD98059, the phosphorylation of ERK was effectively inhibited as well as the nuclear translocation of YB-1 and the expression of mdr1 gene.ConclusionDoxorubicin can increase expression of mdr1/P-glycoprotein through activating MAPK/ERK transduction pathway, then increasing expression of YB-1, inducing YB-1 nuclear translocation, and enhancing DNA-binding activity of YB-1. Multidrug resistance (MDR) in human B-cell lymphoma constitutes a major obstacle to the effectiveness of chemotherapy. The aim of this study was to investigate the molecular mechanism of MDR in B-cell lymphoma. The B-cell lymphoma MDR sublines were developed by exposing the parental Daudi cells to stepwise increasing concentrations of doxorubicin. Interaction of Y-box binding protein-1 (YB-1) with the Y-box motif of the mdr1 gene promoters was studied by electrophoretic mobility shift assay. The effects of YB-1 on mdr1 promoter activity were examined by luciferase assay. After silencing of YB-1 gene by shRNA, the role of YB-1 nuclear translocation in the formation of induced MDR was examined. Expression of mdr1 and YB-1 was examined further after Daudi cells were pretreated with mitogen-activated protein kinase (MAPK) inhibitor PD98059 for 1 hour. Doxorubicin-resistant sublines was generated from the Daudi cell line by stepwise selection in doxorubicin. We found that acquisition of MDR is associated with enhanced YB-1 nuclear translocation and MAPK/extracellular signal-regulated kinase (ERK) activity. Electrophoretic mobility shift assay revealed that doxorubicin increased binding of YB-1 to the Y-box of mdr1 promoter. Luciferase reporter assays demonstrated that the Y-box region is essential for YB-1 regulation of mdr1 expression. The introduction of exogenous YB-1 shRNA into Daudi cells resulted in decreased levels of the expression of mdr1 gene and P-glycoprotein induced by doxorubicin. When Daudi cells were pretreated with MAPK inhibitor PD98059, the phosphorylation of ERK was effectively inhibited as well as the nuclear translocation of YB-1 and the expression of mdr1 gene. Doxorubicin can increase expression of mdr1/P-glycoprotein through activating MAPK/ERK transduction pathway, then increasing expression of YB-1, inducing YB-1 nuclear translocation, and enhancing DNA-binding activity of YB-1." @default.
• W1988723429 created "2016-06-24" @default.
• W1988723429 creator A5002354726 @default.
• W1988723429 creator A5036576535 @default.
• W1988723429 creator A5038836334 @default.
• W1988723429 creator A5059592201 @default.
• W1988723429 creator A5061829183 @default.
• W1988723429 creator A5073347540 @default.
• W1988723429 creator A5074775577 @default.
• W1988723429 creator A5076103759 @default.
• W1988723429 creator A5090351875 @default.
• W1988723429 date "2011-05-01" @default.
• W1988723429 modified "2023-10-15" @default.
• W1988723429 title "Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma" @default.
• W1988723429 cites W1480389906 @default.
• W1988723429 cites W1994008150 @default.
• W1988723429 cites W1996766158 @default.
• W1988723429 cites W1999245993 @default.
• W1988723429 cites W2005260875 @default.
• W1988723429 cites W2006434892 @default.
• W1988723429 cites W2007951687 @default.
• W1988723429 cites W2023669293 @default.
• W1988723429 cites W2027604346 @default.
• W1988723429 cites W2035821927 @default.
• W1988723429 cites W2038871406 @default.
• W1988723429 cites W2039558513 @default.
• W1988723429 cites W2040988771 @default.
• W1988723429 cites W2050194267 @default.
• W1988723429 cites W2059399555 @default.
• W1988723429 cites W2072296682 @default.
• W1988723429 cites W2087711359 @default.
• W1988723429 cites W2092388342 @default.
• W1988723429 cites W2106424708 @default.
• W1988723429 cites W2117321015 @default.
• W1988723429 cites W2121673648 @default.
• W1988723429 cites W2126910403 @default.
• W1988723429 cites W2127564111 @default.
• W1988723429 cites W2132349803 @default.
• W1988723429 cites W2139627575 @default.
• W1988723429 cites W2153405901 @default.
• W1988723429 cites W2159953901 @default.
• W1988723429 cites W2170776146 @default.
• W1988723429 cites W2227630971 @default.
• W1988723429 cites W2414305690 @default.
• W1988723429 doi "https://doi.org/10.1016/j.exphem.2011.01.013" @default.
• W1988723429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21300134" @default.
• W1988723429 hasPublicationYear "2011" @default.
• W1988723429 type Work @default.
• W1988723429 sameAs 1988723429 @default.
• W1988723429 citedByCount "66" @default.
• W1988723429 countsByYear W19887234292012 @default.
• W1988723429 countsByYear W19887234292013 @default.
• W1988723429 countsByYear W19887234292014 @default.
• W1988723429 countsByYear W19887234292015 @default.
• W1988723429 countsByYear W19887234292016 @default.
• W1988723429 countsByYear W19887234292017 @default.
• W1988723429 countsByYear W19887234292018 @default.
• W1988723429 countsByYear W19887234292019 @default.
• W1988723429 countsByYear W19887234292020 @default.
• W1988723429 countsByYear W19887234292021 @default.
• W1988723429 countsByYear W19887234292022 @default.
• W1988723429 countsByYear W19887234292023 @default.
• W1988723429 crossrefType "journal-article" @default.
• W1988723429 hasAuthorship W1988723429A5002354726 @default.
• W1988723429 hasAuthorship W1988723429A5036576535 @default.
• W1988723429 hasAuthorship W1988723429A5038836334 @default.
• W1988723429 hasAuthorship W1988723429A5059592201 @default.
• W1988723429 hasAuthorship W1988723429A5061829183 @default.
• W1988723429 hasAuthorship W1988723429A5073347540 @default.
• W1988723429 hasAuthorship W1988723429A5074775577 @default.
• W1988723429 hasAuthorship W1988723429A5076103759 @default.
• W1988723429 hasAuthorship W1988723429A5090351875 @default.
• W1988723429 hasBestOaLocation W19887234291 @default.
• W1988723429 hasConcept C104317684 @default.
• W1988723429 hasConcept C119056186 @default.
• W1988723429 hasConcept C150194340 @default.
• W1988723429 hasConcept C153911025 @default.
• W1988723429 hasConcept C173396325 @default.
• W1988723429 hasConcept C183978625 @default.
• W1988723429 hasConcept C184235292 @default.
• W1988723429 hasConcept C185592680 @default.
• W1988723429 hasConcept C190232843 @default.
• W1988723429 hasConcept C2776694085 @default.
• W1988723429 hasConcept C2781249067 @default.
• W1988723429 hasConcept C2781303535 @default.
• W1988723429 hasConcept C502942594 @default.
• W1988723429 hasConcept C54009773 @default.
• W1988723429 hasConcept C54355233 @default.
• W1988723429 hasConcept C55493867 @default.
• W1988723429 hasConcept C57074206 @default.
• W1988723429 hasConcept C62478195 @default.
• W1988723429 hasConcept C81885089 @default.
• W1988723429 hasConcept C86803240 @default.
• W1988723429 hasConcept C95444343 @default.
• W1988723429 hasConceptScore W1988723429C104317684 @default.
• W1988723429 hasConceptScore W1988723429C119056186 @default.
• W1988723429 hasConceptScore W1988723429C150194340 @default.
• W1988723429 hasConceptScore W1988723429C153911025 @default.

• next